Skip to main content

Table 1 Associations between Fluorescent oxidation products level at EGEA2 and evolution of asthma characteristics

From: High level of fluorescent oxidation products and worsening of asthma control over time

Evolution of asthma characteristics Fluorescent oxidation products (RFU/mL)
n OR (95% CI) ORadjusted (95% CI)
Persistent vs Improved (ref)
 Current asthmaa 355 vs 38 1.30 (0.86–1.98) 1.19 (0.79–1.80)
 Asthma attacksa 115 vs 53 1.07 (0.74–1.53) 1.13 (0.74–1.72)
 Poor asthma controlb 82 vs 31 0.93 (0.58–1.47) 0.84 (0.48–1.44)
Worsened vs Stable (ref)
 Current asthmaa 18 vs 31 0.95 (0.54–1.66) 0.73 (0.39–1.39)
 Asthma attacksa 51 vs 202 1.10 (0.76–1.60) 1.08 (0.72–1.60)
 Poor asthma controlb 46 vs 68 2.31 (1.33–4.00) 2.27 (1.32–3.90)
  1. OR odds ratio expressed for an increase corresponding to the value of the interquartile range (distance between the 25th and 75th percentile) of FlOPs; adjusted for age, sex and smoking status. Results are presented as “Persistent versus Improved” (reference) and “Worsened versus Stable” (reference) between EGEA2 and EGEA3
  2. aamong 489 participants with ever asthma at both surveys; bamong 355 participants with current asthma at both surveys
  3. Asthma attacks was defined by a positive answer to the following question: “Have you had an asthma attack in the last 12 months?
  4. Results in bold are statistically significant